Delisting risk
RedHill Biopharma (ADR)
Specialty biopharmaceutical developer behind Talicia and a partner-led oral-medicine pipeline.
$0.7990
Pre-market−0.11 (−12.38%)
At close$0.9119(+37.96%)
In millions of USD, except per-share figures
| In millions | Q3 FY22Sep 2022 | Q4 FY22Dec 2022 | Q1 FY23Mar 2023 | Q2 FY23Jun 2023 | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18 | 13 | 4 | 2 | 1 | 1 | 1 | 1 | 3 | 3 | 2 | 2 |
| Cost of revenue | 9 | 9 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Gross profit | 8 | 4 | 2 | 1 | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 1 |
| 15 | 14 | −27 | 5 | 6 | 6 | 5 | 5 | 5 | 5 | 3 | 3 | |
| Research & development | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| 14 | 13 | 11 | 8 | 6 | 6 | 4 | 4 | 3 | 3 | 3 | 3 | |
| Selling & marketing | 7 | −20 | 5 | 5 | 3 | 3 | 2 | 2 | 1 | 1 | 1 | 1 |
| General & administrative | 7 | 33 | 6 | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 |
| Other expenses | 0 | 0 | −39 | −4 | −1 | −1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Operating income | −7 | −10 | 29 | −4 | −6 | −6 | −4 | −4 | −3 | −3 | −2 | −2 |
| −29 | 6 | 21 | 5 | −8 | −8 | 3 | 3 | 0 | 0 | 0 | 0 | |
| Interest income | 3 | 0 | 22 | 7 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Interest expense | 32 | 1 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 |
| Other non-operating income | −3 | −8 | −22 | −7 | 0 | 0 | 0 | 0 | −1 | −1 | 0 | 0 |
| Income before tax | −36 | −4 | 50 | 1 | −14 | −14 | −2 | −2 | −3 | −3 | −2 | −2 |
| Net income from continuing operations | −36 | −4 | 50 | 1 | −14 | −14 | −2 | −2 | −3 | −3 | −2 | −2 |
| Net income | −36 | −4 | 50 | 1 | −14 | −14 | −2 | −2 | −3 | −3 | −2 | −2 |
| EPS, basic | −$282.00 | −$20.00 | $256.00 | $3.00 | −$24.00 | −$17.00 | −$1.00 | −$1.00 | −$1.00 | −$1.00 | −$1.00 | −$1.00 |
| EPS, diluted | −$282.00 | −$20.00 | $256.00 | $3.00 | −$24.00 | −$17.00 | −$1.00 | −$1.00 | −$1.00 | −$1.00 | −$1.00 | −$1.00 |
| Weighted average shares, basic | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 2 | 2 |
| Weighted average shares, diluted | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 3 | 2 | 2 |
| EBITDA | −2 | 0 | 111 | 3 | −6 | −6 | −4 | −4 | −2 | −2 | −2 | −2 |
| Depreciation & amortization | 2 | 2 | 60 | −59 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −4 | −2 | 51 | 3 | −6 | −6 | −4 | −4 | −2 | −2 | −2 | −2 |